Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - oxybutynin hydrochloride - tablet - 2.5 milligram(s) - drugs for urinary frequency and incontinence; oxybutynin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - oxybutynin hydrochloride - tablet - 5 milligram(s) - drugs for urinary frequency and incontinence; oxybutynin

Ireland - English - HPRA (Health Products Regulatory Authority)

syri pharma limited t/a thame laboratories - oxybutynin hydrochloride - oral solution - 2.5 mg/5ml - drugs for urinary frequency and incontinence; oxybutynin

Ireland - English - HPRA (Health Products Regulatory Authority)

syri pharma limited t/a thame laboratories - oxybutynin hydrochloride - oral solution - 5 mg/5ml - drugs for urinary frequency and incontinence; oxybutynin

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - oxybutynin hydrochloride 5mg (plus 2% overage to allow for water content) - tablet - 5 mg - active: oxybutynin hydrochloride 5mg (plus 2% overage to allow for water content) excipient: brilliant blue fcf lactose monohydrate magnesium stearate microcrystalline cellulose - oxybutynin chloride is indicated in adults and children over 5 years of age for the management of urgency and incontinence that characterise neurogenic bladder disorders and idiopathic destrusor instability.

New Zealand - English - Medsafe (Medicines Safety Authority)

ethos consulting group - oxybutynin hydrochloride 2.5mg;  ;   - tablet - 2.5 mg - active: oxybutynin hydrochloride 2.5mg     excipient: crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose - oxybutynin ade is primarily indicated for the management of urgency and incontinence that characterise neurogenic bladder disorders and idiopathic detrusor instability.

New Zealand - English - Medsafe (Medicines Safety Authority)

ethos consulting group - oxybutynin hydrochloride 5mg;  ;   - tablet - 5 mg - active: oxybutynin hydrochloride 5mg     excipient: crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose - oxybutynin ade is primarily indicated for the management of urgency and incontinence that characterise neurogenic bladder disorders and idiopathic detrusor instability.

United Kingdom - English - myHealthbox

syri limited - oxybutynin hydrochloride - oral solution - 5mg/5ml - anticholinergic as well as antispasmodic - urinary incontinence, urgency and frequency in the unstable bladder, whether due to neurogenic bladder disorders (detrusor hyperreflexia) in conditions such as multiple sclerosis and spina bifida, or to idiopathic detrusor instability (motor urge incontinence).

Canada - English - Health Canada

janssen inc - oxybutynin chloride - syrup - 1mg - oxybutynin chloride 1mg - antimuscarinics

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride 5 mg - oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). oxybutynin chloride is contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. oxybutynin chloride is also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product.